The pharmacological and surgical management of adults with obesity

Journal of Family Practice

Volumn 63, Issue 7, 2014, Pages

  Ryan, Donna H ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; TETRAHYDROLIPSTATIN;

ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BARIATRIC SURGERY; BEHAVIOR THERAPY; BILIOPANCREATIC BYPASS; BODY MASS; CARDIOVASCULAR RISK; CONSTIPATION; DEFECATION URGENCY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ENERGY BALANCE; FATIGUE; FLATULENCE; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; IRRITABILITY; LIFESTYLE MODIFICATION; LIVER INJURY; LONG TERM CARE; LOW CALORY DIET; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROLITHIASIS; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEROTONIN SYNDROME; SIDE EFFECT; SLEEVE GASTRECTOMY; STOMACH BYPASS; SYSTEMATIC REVIEW (TOPIC); UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BARIATRIC SURGERY; BENZAZEPINES; FRUCTOSE; HUMANS; LACTONES; MIDDLE AGED; OBESITY; PHENTERMINE;

EID: 84904999910     PISSN: 00943509     EISSN: 15337294     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374-1383. (Pubitemid 46871141)
2. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria C, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. November 2013:1-69.
3. Bariatric surgery. Common concerns. Summit Health. http://www. summithealth. org/services/bariatric/common-concerns. Published 2014. Accessed June 6, 2014.
4. Fitch A, Everling L, Fox C, et al. Institute for Clinical Systems Improvement. Health care guideline: Prevention and management of obesity for adults. https://www.icsi. org/-asset/s935hy/ObesityAdults.pdf. Published 2013. Accessed June 6, 2014.
5. Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med. 2011;365(21):1969- 1979.
6. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111- 2120. (Pubitemid 41653103)
7. Xenical [package insert]. Nutley, NJ: Roche Laboratories, Inc.; 2009.
8. Belviq [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2012.
9. Qsymia [package insert]. Mountain View, CA: Vivus, Inc.; 2012.
10. Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837-845.
11. Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther. 2011;89(5):683-692.
12. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161. (Pubitemid 38196725)
13. Xenical [package insert]. South San Francisco, CA: Genentech, Inc.; 2012.
14. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256.
15. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-3077.
16. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426-1436.
17. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
18. Garvey WT, Ryan DH, Look M et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308.
19. Allison DB, Gadde KM, Garvey WT et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342.
20. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echo-cardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560-567.
21. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, doubleblind, placebo-controlled study of an oral, extended-release formulation of phentermine/ topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35(11):1529-1539.
22. Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). Am J Cardiol. 2013;111(8):1131-1138.
23. Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207(5):405.e1-405. e7.
24. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752. (Pubitemid 47295641)
25. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934.
26. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: An updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275-287.
27. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Endocr Pract. 2013;19(2):337-372.